Oral fluconazole for empiric treatment of prolonged Fever in neutropenic patients: prospective study in 250 consecutive patients after stem cell transplantation.
Neutropenic patients who continue to be febrile despite adequate broad-spectrum antibacterial treatment require empirical antifungal therapy. The aim of the present study was to evaluate the safety and efficacy of oral fluconazole for empirical antifungal therapy in neutropenic patients with persistent fever. A prospective cohort design was used. The study sample included 250 consecutive patients with high-risk stage II, III, or responding metastatic breast cancer who received high-dose chemotherapy (HDC) with autologous peripheral blood progenitor stem cell transplantation. Those with neutropenic fever lasting more than 72 hours despite broad-spectrum antibacterial coverage were treated with fluconazole. Treatment was continued until fever dropped and/or neutrophil count recovered with blood cultures remaining negative. Antifungal treatment was required in 173 patients (69%). There were no cases of documented deep systemic fungal infection. Two patients (<1%) had positive blood cultures for fungi. None of the patients experienced toxicity related to fluconazole. There was one transplant-related death. Thirty-one patients (18%) were unable to complete the oral fluconazole protocol because of severe mucositis, and they received intravenous fluconazole at the same dose, with similar efficacy. Oral fluconazole is a safe and effective alternative to amphotericin B for empirical early antifungal treatment in persistent neutropenic fever in breast cancer patients undergoing HDC with autologous stem cell support. Further study of oral fluconazole and amphotericin B as empirical agents in other groups of patients with persistent neutropenic fever is warranted.
Stemmer
Salomon M
SM
Bone Marrow Transplant Service, Department of Oncology and Radiotherapy, Chaim Sheba Medical Center, Tel Hashomer, Israel. sstemmer@barak-online.net
Maor
Yasmin
Y
Hardan
Izhar
I
D000284:Administration, Oral; D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000276:immunology / Q000628:therapy; D018567:Breast Neoplasms, Male / Q000276:immunology / Q000628:therapy; D016190:Carboplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D005260:Female; D005334:Fever / Q000209:etiology; D015725:Fluconazole / Q000627:therapeutic use*; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009503:Neutropenia / Q000209:etiology; D009894:Opportunistic Infections / Q000188:drug therapy*; D036102:Peripheral Blood Stem Cell Transplantation / Q000009:adverse effects; D011446:Prospective Studies; D013852:Thiotepa / Q000008:administration & dosage; D014182:Transplantation, Autologous
D000900:Anti-Bacterial Agents; D000935:Antifungal Agents; D016179:Granulocyte Colony-Stimulating Factor; D003520:Cyclophosphamide; D015725:Fluconazole; D013852:Thiotepa; D016190:Carboplatin